Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial
Sylvie Lorenzen(Technical University of Munich), Timo Gaiser(University of Mannheim), Maria Loose(Krankenhaus Nordwest), Claudia Pauligk(Goethe University Frankfurt), Nils Homann(Fraunhofer Project Centre Wolfsburg), Alexander Siebenhüner(Klinik Hirslanden), Eray Goekkurt(Sorbonne Université), Georg Martin Haag(Heidelberg University), Disorn Sookthai(Krankenhaus Nordwest), Vera Heuer(St. Anna Hospital), Matthias Biebl(Charité - Universitätsmedizin Berlin), Christina Kopp(Krankenhaus Nordwest), Wolf O. Bechstein(Goethe University Frankfurt), Moustafa Elshafei(Krankenhaus Nordwest), Claus Bolling(Agaplesion Markus Hospital), Ralf‐Dieter Hofheinz(Goethe University Frankfurt), Jorge Riera‐Knorrenschild, Thomas J. Ettrich(University Hospital Ulm), Salah‐Eddin Al‐Batran(Krankenhaus Nordwest), Tianzuo Zhan(German Cancer Research Center), Peter Thuss‐Patience(Charité - Universitätsmedizin Berlin), Udo Lindig(Jena University Hospital), Stefan Angermeier(Klinikum Ludwigsburg), Michael Schenk(Krankenhaus Barmherzige Brüder), Thorsten Oliver Götze(Goethe University Frankfurt), Albrecht Kretzschmar(Praxis für Hämatologie und Onkologie)
Cited by 192
Related Papers
Wnt signaling in cancer
|Oncogene|2016|2.6k
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k